Biomarkers associated with physical decline in silicosis patients and their uses

By identifying Vibrio as a biomarker, the accuracy of physical decay diagnosis in silicosis patients was solved, and efficient physical decay diagnosis and treatment in silicosis patients was achieved, reducing the physical decay status of silicosis patients.

CN116904575BActive Publication Date: 2024-11-22SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310830938.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-07-07
Publication Date
2024-11-22
Estimated Expiration
2043-07-07

AI Technical Summary

Technical Problem

The prior art has failed to effectively identify and distinguish between physical deterioration and non-physical deterioration in patients with silicosis, resulting in increased diagnostic errors and treatment difficulties.

Method used

Vibrio as a biomarker, by detecting the abundance of microbial markers in bronchial alveolar lavage fluid, using 16S sequencing, whole genome sequencing, quantitative polymerase chain reaction and other methods, diagnostic reagents and pharmaceutical compositions are developed to predict and physical decline in patients with silicosis.

Benefits of technology

It has achieved an early accurate diagnosis of physical decay in patients with silicosis, which is highly sensitive, specific and accurate, providing a basis for targeted treatment, and reducing the physical decay status of patients with silicosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116904575B_ABST
    Figure CN116904575B_ABST
Patent Text Reader

Abstract

The present invention discloses a biomarker related to physical decline of silicosis patients and its use. The present invention first discovered that Vibrio can be used as a diagnostic marker for physical decline of silicosis patients, has good diagnostic efficacy, and the AUC value is as high as 0.938. It has the advantages of high accuracy, high sensitivity, high specificity, etc., and can be used for early diagnosis or auxiliary diagnosis of physical decline of silicosis patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine and molecular biology, and in particular to biomarkers associated with physical decline in silicosis patients and uses thereof. Background Art

[0002] Silicosis is a common type of pneumoconiosis, an occupational-related fibrotic lung disease usually caused by occupational exposure to respirable crystalline silica and hazardous dusts. Crystalline silica is a common component of sand, so occupational exposure mainly occurs in the construction and stone processing industries. When respirable crystalline silica is inhaled, it triggers an inflammatory process and produces reactive oxygen species, which can lead to fibrosis and carcinogenesis. Silicosis is progressive, irreversible, and incurable, and treatment options for severe silicosis are still very limited, which has placed a huge medical burden on the medical field.

[0003] Physical decline is the main symptom of silicosis, which seriously affects the patient's work efficiency and quality of life, and has become a serious occupational health hazard worldwide. Because the physical decline of silicosis patients may be caused by the degree of lung function, gas exchange disorders or radiological changes. Therefore, distinguishing silicosis patients with physical decline from those without physical decline is of great significance for the course of silicosis patients and subsequent targeted treatment.

[0004] Biomarkers are substances with specific characteristics or changes produced in organisms, which can be used as indicators for diagnosing, predicting, monitoring and evaluating the physiological state or disease risk of organisms. Biomarkers can be substances produced by molecules, cells, tissues, bacteria, fungi or whole organisms, and their changes can be associated with disease development, treatment effects, drug metabolism, etc., so they can be used to diagnose and monitor diseases, evaluate treatment effects, and guide individualized treatment strategies. Previous studies have shown that lung bacteria and fungi play an important role in maintaining lung homeostasis, and they may also be crucial in the development of silicosis, but there are currently no reports on the correlation between bacterial or fungal communities and whether or not patients with silicosis have symptoms of physical decline.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide biomarkers related to the physical decline of silicosis patients and their uses. The microbial markers of the present invention have good sensitivity in predicting the physical decline of silicosis patients. It is only necessary to obtain the relative content of the microbial markers as an auxiliary diagnosis, guide the adjustment of the microbial environment, and improve the physical decline of silicosis patients.

[0007] The present invention is achieved in that:

[0008] In a first aspect, the present invention provides the use of a reagent for detecting the abundance of a biomarker in a sample in the preparation of a product for diagnosing physical decline in patients with silicosis, wherein the microbial marker comprises Vibrio.

[0009] In some embodiments, the sample is bronchoalveolar lavage fluid (BALF).

[0010] In some embodiments, the above reagents include reagents for detecting the content or abundance of biomarkers in a sample by 16S sequencing, whole genome sequencing, quantitative polymerase chain reaction, PCR-pyrophosphate sequencing, fluorescence in situ hybridization, microarray or PCR-ELISA.

[0011] In some embodiments, the reagents include primers, probes, antisense oligonucleotides, aptamers or antibodies specific to the biomarkers.

[0012] In some embodiments, the above-mentioned product includes a kit, a test paper, or a chip.

[0013] In a second aspect, the present invention also provides a product for predicting or diagnosing physical decline in silicosis patients, the diagnostic product comprising a reagent for detecting the content or abundance of a biomarker in a sample of a subject, and the biomarker comprises Vibrio.

[0014] In some embodiments, the above reagents include reagents for detecting the content or abundance of biomarkers in a subject's sample by 16S sequencing, whole genome sequencing, quantitative polymerase chain reaction, PCR-pyrophosphate sequencing, fluorescence in situ hybridization, microarray or PCR-ELISA.

[0015] In some embodiments, the reagents include primers, probes, antisense oligonucleotides, aptamers or antibodies specific to the biomarkers.

[0016] In some embodiments, the above-mentioned product includes a kit, a test paper, or a chip.

[0017] In a third aspect, the present invention further provides a pharmaceutical composition for preventing and / or treating physical decline in patients with silicosis, wherein the pharmaceutical composition comprises a substance capable of reducing the content or abundance of Vibrio.

[0018] In a fourth aspect, the present invention also provides a method for screening candidate drugs for preventing and / or treating physical decline in silicosis patients, comprising the following steps:

[0019] A system expressing or containing Vibrio is treated with the substance to be screened, and the content or abundance of Vibrio in the system is detected. If the substance to be screened can reduce the content or abundance of Vibrio, it indicates that the substance to be screened is a candidate drug for preventing and / or treating physical decline in silicosis patients.

[0020] In a fifth aspect, the present invention also provides the use of the biomarker Vibrio in screening candidate drugs for preventing and / or treating physical decline in silicosis patients.

[0021] The present invention has the following beneficial effects:

[0022] The present invention discovers for the first time that the microbial marker Vibrio can be used as a diagnostic marker for physical decline in patients with silicosis, has good diagnostic efficacy, and an AUC value of up to 0.938. It has the advantages of high accuracy, high sensitivity, and high specificity, and can be used for early diagnosis or auxiliary diagnosis of physical decline in patients with silicosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0024] Figure 1 shows the profile of BALF bacterial flora in silicosis patients with and without physical decline (physical decline vs. without physical decline, n = 81); AE: alpha diversity analysis; Figure 1A : Chao Index, Figure 1B :ACE Index, Figure 1C :Sobs index, Figure 1D : Shannon index, Figure 1E : Simpson index; Figure 1F : Venn analysis at the gate level; Figure 1G : Venn analysis at genus level; Figure 1H :Circus analysis at gate level; Fig. 1I :Circus analysis at genus level; Figure 1J : PCA analysis at genus level; Figure 1K : PCoA analysis at the genus level; Figure 1L :LEfSe cladogram from phylum to genus; Figure 1M : LEfSe analysis at the gate level; Figure 1N : LEfSe analysis at the genus level.

[0025] Figure 2 shows the distribution of BALF flora in silicosis patients with and without physical decline (physical decline vs. without physical decline, n = 100); AE: α diversity analysis; Figure 2A : Chao Index, Figure 2B :ACE Index, Figure 2C :Sobs index, Figure 2D: Shannon index, Figure 2E : Simpson index, Figure 2F : Venn analysis at the gate level; Figure 2G : Venn analysis at genus level; Figure 2H : Circus analysis at the gate level; Fig.2I : Circus analysis at genus level; Figure 2J : PCA analysis at genus level; Figure 2K : PCoA analysis at genus level; Figure 2L : LEfSe cladogram from phylum to genus; Figure 2M : Analysis of LEfSe at the phylum level; Figure 2N : Analysis of LEfSe at the genus level.

[0026] Figure 3 This is a prediction analysis of PICRUSt2 on silicosis patients with and without physical decline (physical decline and no physical decline, n = 81); PICRUSt2 is a software that predicts functional abundance from marker gene (generally 16S rRNA) sequencing data. The graph is a violin plot, which can be used to display the distribution status and probability density of multiple groups of data. It consists of an internal box plot and an external kernel density plot. The larger the area of ​​a certain area, the greater the probability of distribution near a certain value. In the figure, red represents patients with physical decline, and green represents patients without physical decline. The horizontal axes are β-glucosidase, NADPH, and NADH, respectively.

[0027] Figure 4 The classification ability of a specific bacterial marker (g-vibrio) associated with physical decline according to ROC analysis; the ROC curve reflects the relationship between sensitivity and specificity, with specificity on the horizontal axis and sensitivity on the vertical axis. The larger the X value and the larger the Y value, the better the accuracy. The area under the curve is called AUC, which is used to indicate the accuracy of the prediction. The higher the AUC value, the better the accuracy of the prediction. Figure 4 The curve is very close to the upper left corner, indicating that the specific bacterial marker (g-vibrio) associated with physical decline has a strong classification ability. DETAILED DESCRIPTION

[0028] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0029] In clinical practice, the physical decline of silicosis patients is based on the subjective statements of the patients and is determined by clinicians based on professional scales. Since the results of the scales are affected by factors such as the patient's mood, social, family, medical environment, and the doctor's judgment, they are prone to fluctuations and are not very stable, so the results of the judgments are subject to errors. Therefore, there is an urgent need to provide a stable, reliable and objective judgment method to assist doctors in judging the severity of patients' physical decline, and then provide targeted treatment for patients.

[0030] The inventors of the present invention found during the experiment that the bacterial and fungal communities in the bronchoalveolar lavage fluid (BALF) of patients with silicosis and patients without silicosis would change β diversity, especially Vibrio, which showed significant differences between patients with silicosis and patients without silicosis, indicating that Vibrio can be used as a predictor of physical decline symptoms in patients with silicosis.

[0031] Based on this, the present invention provides the use of a reagent for detecting the abundance of a biomarker in a sample in the preparation of a product for diagnosing physical decline in silicosis patients. Specifically, the biomarker is Vibrio.

[0032] The following provides definitions of some terms used in this specification. Unless otherwise defined, all technical and scientific terms used in the present invention generally have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs.

[0033] The term "bronchoalveolar lavage fluid" used in the present invention refers to the alveolar surface lining fluid collected after lavage of lung segments and lung subsegments using a fiberoptic bronchoscope. After collection, cytology, soluble substances, microorganisms and parasites, as well as biochemical and immunological tests can be performed, which is of great value in the diagnosis, condition observation and prognosis of lower respiratory tract diseases.

[0034] The term "abundance" as used herein refers to a measure of the number of target microorganisms in a biological sample. "Abundance" is also referred to as "load". Bacterial quantification is generally performed by molecular methods, typically by measuring the 16S rRNA gene copy number of the target microorganism, such as by fluorescence in situ hybridization (FISH), quantitative polymerase chain reaction (qPCR) or PCR / pyrosequencing.

[0035] In the present invention, the reagent for detecting the content or abundance of a biomarker in a sample of a subject can be a primer, and the method of sequence amplification using the primer can be, for example, polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), multiplex PCR, touchdown PCR, hot start PCR, nested PCR, enhanced PCR, real-time PCR, differential PCR, rapid amplification of cDNA ends, reverse polymerase chain reaction, vector-mediated PCR, thermal asymmetric staggered PCR, ligase chain reaction, repair chain reaction, transcription-mediated amplification, autonomous sequence replication, and selective amplification reaction of the target base sequence.

[0036] In the present invention, the term "primer" refers to a 7 to 50 nucleic acid sequence that can form a base pair complementary to a template chain and acts as a starting point for replicating the template chain. Primers are usually synthesized, but naturally occurring nucleic acids can also be used. The sequence of the primer does not necessarily need to be exactly the same as the sequence of the template, as long as it is sufficiently complementary and can hybridize with the template. Additional features that do not change the basic properties of the primer can be mixed in. Examples of additional features that can be mixed in include methylation, capping, replacement of more than one nucleic acid by a homolog, and modification between nucleic acids, but are not limited to these.

[0037] In the present invention, the reagent for detecting the content or abundance of the biomarker in the subject sample can be an antibody, and by using an immunological method based on the antigen-antibody reaction, the corresponding microorganism can be detected or the microorganism level can be measured. As the analytical method used for this, there are protein blotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA: Radioimmunoassay), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, fluorescence activated cell sorter (FACS), protein chip, etc. The above methods are only an explanation of the antibody-antigen immune reaction, and the present invention is not limited to the above methods.

[0038] As used herein, the term "diagnosis" refers to distinguishing or identifying a disease, syndrome or condition, or to distinguishing or identifying a person suffering from a particular disease, syndrome or condition. In an illustrative embodiment of the invention, silicosis performance decline in a subject is diagnosed based on analyzing microbiota markers in a sample.

[0039] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0040] Example 1

[0041] This example is to screen for bacteria associated with silicosis physical decline

[0042] 1. Research subjects and sample collection

[0043] The study population of this example includes males diagnosed with silicosis according to the clinical guidelines of "Diagnosis of Occupational Pneumoconiosis" (GBZ70-2015), mainly from the core area of ​​Sichuan.

[0044] The inclusion criteria for the participants of this example are: 1) adult male workers diagnosed with silicosis by a doctor; 2) planning to undergo lung lavage treatment.

[0045] The exclusion criteria for participants in this example are: 1) antibiotics have been used within 4 weeks; 2) the constructed library is not suitable for sequencing, then the participant is excluded.

[0046] This example uses a questionnaire survey to collect basic information and health status of the participants. Ten consecutive silicosis patients from the only tertiary occupational disease hospital in China, West China Fourth Hospital, from 2019 to 2020 were included in this example. Half of the patients experienced physical decline, while the other half did not.

[0047] Diagnostic criteria for physical decline: References Jacobson DNO, Lowing K, Tedroff K. Health-related quality of life, pain, and fatigue in young adults with cerebral palsy. Dev Med Child Neurol 2020;62:372-8.

[0048] Inclusion criteria: Patients were clearly diagnosed with silicosis and physical decline and met the above diagnostic criteria.

[0049] The reason why a non-silicosis control group is not included in this embodiment is that the application for lung lavage in healthy people did not obtain ethical approval in this pilot study. In addition, silicosis is an interstitial lung disease caused by inhalation of industrial silica dust. Whole lung lavage is an effective treatment method for removing exogenous dust, inflammatory factors and proinflammatory cells from the lungs. Other interstitial lung diseases caused by drugs, autoimmunity, and radiotherapy (rays) are not caused by exogenous dust, so whole lung lavage is rarely used. At the same time, other types of BALF samples may not come from large-volume lung lavage fluid (20L). If used as a control for this study, due to differences in lung lavage operations, its comparability is not strong.

[0050] The reason for using 10 silicosis patients to obtain a total of 100 BALF specimens is that in microbiome research, homogeneity is very important to help control confounding factors and improve the accuracy of the results, so in this example, homogeneous chronic silicosis patients at the same stage were selected as much as possible. In other words, there are not many homogeneous silicosis patients who can meet the inclusion and exclusion requirements.

[0051] The Ethics Committee of West China School of Public Health / West China Fourth Hospital, Sichuan University approved this study (IRB number: HXSY-EC-2020073). All subjects signed informed consent before lung lavage. The institutional review board waived the requirement for written informed consent for this study. The participant information has been fully anonymized. The patients and others are unaware of the patients. A total of 100 BALF specimens were collected from 10 consecutive patients with silicosis who met the inclusion requirements from West China Fourth Hospital. The basic information of the patients is shown in Tables 1, 2, and 3.

[0052] Table 1 Basic information and symptoms of patients

[0053]

[0054]

[0055] Table 2 Results of blood routine examination of patients

[0056]

[0057] Table 3 Results of blood biochemical identification of patients

[0058]

[0059]

[0060] Note: 1, wofatigue: silicosis patients have no physical decline; 2, fatigue: silicosis patients have physical decline; 3: all: ten patients; 4, rank sum test, when P value < 0.05.

[0061] 30,981 and 67,698 qualified reads were randomly selected from each sample for bacterial flora and fungal flora analysis, respectively. Finally, 2,509,461 (30,981 reads / sample × 81) and 6,769,800 (67,698 reads / sample × 100) amplicon sequence variants (ASVs) were obtained for bacterial and fungal flora analysis.

[0062] After the patient was placed under general anesthesia, a specialist performed lung lavage. Each lung was lavaged 10 times with 1L of sterile saline at 37°C. 600mL of lavage fluid was collected from the left lung in each round. The samples were placed on ice and transported to the laboratory within one hour. Each sample was centrifuged at 13,000g for 2 minutes at 4°C in a 50mL centrifuge tube. The pellet was then stored at -80°C.

[0063] 2. DNA Extraction

[0064] Total genomic DNA samples were extracted using the Zymo Bacterial / Fungal DNA Mini Prep Kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's instructions and stored at -80°C until further analysis. The quantity and quality of the extracted DNA were determined using a NanoDrop ND-1000 spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA) and agarose gel electrophoresis, respectively.

[0065] 3. Library construction, sequencing and analysis of bacterial and fungal flora

[0066] The 16SrRNA gene was amplified with barcode 338F: 5'-actcctacggggaggcagca-3' and 806R: 5'-ggactachvggggtwtctaat-3'. The ITS1 gene 5F: 5'-ggaagtaaaagtcgtaacaagg-3' and ITS12R: 5'-gctgctttctcatcgatgc-3' were amplified with barcode ITS1. DNA libraries were constructed according to previous studies. Amplicons were collected and sequenced on Illumina Novasek PE250 (Illumina, Inc., San Diego, CA, USA) platform. Sequencing data were processed with integrated pipelines for bioinformatics analysis.

[0067] 4. Bioinformatics Analysis

[0068] (1) Off-line data cleaning and annotation

[0069] Data processing:

[0070] The original sequencing sequence was quality controlled using fastp (https: / / github.com / OpenGene / fastp, version 0.20.0) software, and spliced ​​using FLASH (http: / / www.cbcb.umd.edu / software / flash, version 1.2.7) software:

[0071] (1) Filter the bases with a quality value of less than 20 at the tail of the reads, set a 50 bp window, and if the average quality value in the window is less than 20, cut off the back end bases from the window, filter the reads below 50 bp after quality control, and remove the reads containing N bases;

[0072] (2) Based on the overlap relationship between PE reads, the paired reads were spliced ​​(merged) into a sequence with a minimum overlap length of 10 bp;

[0073] (3) The maximum mismatch ratio allowed in the overlap region of the spliced ​​sequence is 0.2, and non-compliant sequences are screened out;

[0074] (4) Samples are distinguished based on the barcodes and primers at both ends of the sequence, and the sequence direction is adjusted. The allowed number of mismatches for the barcode is 0, and the maximum number of mismatches for the primers is 2.

[0075] The UPARSE software (http: / / drive5.com / uparse / , version 7.1) was used to cluster the sequences into OTUs and remove chimeras based on a similarity of 97%. The RDP classifier (http: / / rdp.cme.msu.edu / , version 2.2) was used to annotate each sequence by species classification and to align it with the Silva 16S rRNA database (version 138), with the alignment threshold set at 70%.

[0076] (2) Species composition analysis

[0077] Species composition refers to all the species that make up a community. Biological variation is caused by combination, such as gene recombination and chromosome combination. A new species occurs through combination. The same species form a population, and different species form a community together, so species composition is an important feature that distinguishes different communities. Combination runs through the entire process of biological evolution. The formation of species is inseparable from combination, and combination creates species. The species composition analysis of this study includes Venn diagrams, species relative abundance bar graphs, etc. The Venn diagram is used to show the connection between different groups of things. By counting the number of shared and unique OTUs in multiple samples, the similarity and overlap of the number of OTUs in environmental samples can be more intuitively expressed. OTUs with a similarity of 97% are generally used for analysis, and R language tools are used for statistics and mapping.

[0078] According to the species abundance table and species annotation table, the species classification with the highest abundance is selected, and the relative abundance is calculated to obtain the relative abundance file. A bar chart of abundance comparison is drawn. The bar chart is presented in the form of a stacked bar chart, which can make the sample abundance comparison more intuitive. The horizontal axis of the result graph is the sample name, and the vertical axis represents the relative abundance of a classification. Different colors correspond to different species at the same level. The bar chart can clearly analyze the composition of highly expressed species in each sample, and the expression trend of species within the group can also be observed.

[0079] (3) Alpha diversity analysis

[0080] Alpha diversity (α-diversity) refers to the average diversity of species in different sites or habitats at a regional scale. This term was coined by Robert Harding Whittaker. He also coined other related terms such as beta diversity (β-diversity) and gamma diversity (γ-diversity). Alpha diversity is considered a fundamental method for analyzing community surveys because there are many perturbations that can affect alpha diversity. In microbial ecology, analyzing alpha diversity in amplicon sequencing data is a common first step in assessing differences in microbial environments. Species richness, the number of species or operational taxonomic units present in an area, is the simplest measure of alpha diversity. The richness of the distribution is clearly evident when using an octave plot. Alpha diversity has been given different definitions by several ecologists. These different definitions may be influenced by different assumptions about species diversity. This is why most researchers have been using more than one diversity index.

[0081] There are two types of Chao Index: Chao 1 and Chao 2. Chao 1 is an abundance-based estimator. Therefore, data involving the abundance of individual samples belonging to a certain class are required. Chao 2, on the other hand, is an association-based estimator, so data specifying the presence or absence of species in the sample are required. The Simpson index is a measure of how concentrated individuals are when they are divided into classes. The Simpson index is equal to the probability that two entities randomly taken from the dataset of interest represent the same type, or to the use and type of alpha diversity measures in microbial NGS. Shannon index, also known as Shannon diversity index or Shannon entropy, is one of the popular diversity indices in the ecological literature. The idea of ​​this metric is that the more different letters there are and the more equal their proportional abundance in the string of interest, the more difficult it is to predict which letter will be the next letter in the string. The Shannon diversity index quantifies the uncertainty in predicting the identity of a species from an individual randomly drawn from a dataset. The ACE index is an abundance-based coverage estimator and is a diversity measure that involves an arbitrary abundance threshold, with Sabun marking the number of abundant taxa and Srare marking the number of rare taxa. Good's Coverage Index is another alpha diversity estimator.

[0082] (4) Beta diversity analysis

[0083] Principal component analysis (PCA) and principal coordinates analysis (PCoA) are two main mathematical procedures or ordination techniques used for multivariate analysis. PCA and PCoA can be used to derive a 2- or 3-dimensional scatter plot of individuals. The geometric distances between individuals in the plot reflect the genetic distances between individuals with minimal distortion. In such a plot, the clustering of individuals will reveal a collection of genetically similar individuals. PCA is defined as "a method of data reduction to clarify the relationship between two or more features and to partition the total variance of the original features into a finite number of new, uncorrelated variables". This allows the differences between individuals to be visualized and possible groups to be identified. These reductions are achieved by linearly transforming the original variables into a set of new, uncorrelated variables, the principal components. The first step in principal component analysis is to calculate the eigenvalues, which define the total amount of variation distributed on the PC axes. The first PC summarizes most of the variation in the original data relative to all the remaining PCs. The second PC explains most of what the first PC does not summarize and is not associated with the first PC, and so on. Since each PC is orthogonal and independent of each other, each PC reveals a different property of the original data and can therefore be interpreted independently. In this way, the total variation of the original data set can be decomposed into cumulative components. The proportion of variation accounted for by each PC is expressed as the eigenvalue divided by the sum of the eigenvalues. The eigenvector defines the relationship between the PC and the original data axes.

[0084] PCA can be performed on two types of data matrices: variance-covariance matrix and correlation matrix. For features of different scales, the correlation matrix of the normalized original data set is preferred. If the features are of the same scale, the variance-covariance matrix can be used. When using both types of matrices, it must be taken into account that the variance-covariance matrix allows the study of absolute variations between individuals. However, for the correlation matrix, only differences relative to the normalized data can be interpreted.

[0085] Principal component analysis can also be used to determine the optimal number of clusters for a study. In this case, the goal is to maximize the variation explained by the first PC of each cluster. The second eigenvalue can be set to 0.75 to determine that the first PC explains most of the variation. PCoA is a scaling or ordination method that starts with a similarity or dissimilarity matrix between a set of individuals and aims to produce a low 3D graphical representation of the data so that the distances between points in the graph are close to the original dispersion. Therefore, the starting point matrix of similarity or dissimilarity for PCoA is different from that of PCA, which starts with an initial data matrix (e.g., the presence and absence of alleles in molecular marker data). When there are relatively few characters and no missing data, the outputs of PCA and PCoA will be similar. However, PCoA is more satisfactory than PCA in handling missing data. In PCA, when calculating the input matrix, each missing value is simply replaced by the mean value of the corresponding character or marker. Therefore, when using PCA, individuals with a large amount of missing data can be grouped closer to the centroid of the group. To overcome the problem of missing data in PCA, the coefficients between two individuals should be calculated separately, using only the characteristics of the two individuals that have been recorded. When there is a lot of missing data and when the number of individuals is less than the number of characters and the current two or three principal components explain most of the variation, principal component analysis and principal coordinate analysis become useful techniques for grouping individuals through scatter plot representation. In principal component analysis or principal coordinate analysis, when the original data are not highly correlated, the first few principal components usually cannot explain much of the original variation. In this case, assessing genetic relationships based on the first two or three principal components may lead to misleading interpretations. To avoid this distortion, the analysis of genetic relationships between individuals should be based on the optimal number of PCs that can explain the maximum amount of variation in the original data. The eigenvalue of the PC can be used as a criterion for determining how many PCs should be used. PCs with eigenvalues ​​> 1.0 are considered to have more intrinsic information than any single original variable alone.

[0086] (5) Analysis of species differences among groups

[0087] LEfSe (Linear discriminant analysis EffectSize) is an analytical tool for discovering and interpreting high-dimensional data biomarkers (classification units, pathways, genes). It can realize the comparison between two or more groups, and can also perform comparative analysis between subgroups within a group, so as to find species with significant differences in abundance between groups. The analysis first uses the non-parametric Kruskal-Wallis rank sum test to find species with significant abundance differences between different groups, and then uses the Wilcoxon rank sum test to analyze the consistency of the differences in the previous step of the difference species in the subgroups of different groups. Finally, linear regression analysis (LDA) is used to estimate the effect of each component abundance on the difference effect. The color in the LDA value distribution bar chart generally represents the corresponding group, and the length of the bar chart represents the contribution of the difference species (LDA score).

[0088] (6) Correlation analysis

[0089] This embodiment uses the Spearman correlation analysis method to analyze the correlation between bacterial diversity and environmental factors. The Spearman rank correlation coefficient uses the rank of two variables for linear correlation analysis. It does not require the distribution of the original variables. It is a non-parametric statistical method with a wide range of applications. If the data has no repeated values ​​and the two variables are completely monotonically correlated, the Spearman rank correlation coefficient is +1 or -1. Even if there are outliers in the Spearman correlation coefficient, the impact on the correlation coefficient is very small because the rank of the outlier usually does not change much. For a sample with a sample size of n, n original data are converted into rank data, and the correlation coefficient ρ is:

[0090]

[0091] 5. Statistical Analysis

[0092] The main statistical analyses were performed using R software (Version 4.1.1, R Core Team, Vienna, Austria) and SPSS (V23.0, Sage IBM, Armonk, NY, USA). Chi-square analysis and Fisher's exact test were used for categorical variables, and t-test and Wilcoxon rank-sum test were used for continuous variables. All tests were two-sided, and P values ​​< 0.05 were considered statistically significant. In addition, P values ​​were adjusted according to the false discovery rate (FDR) in the analysis of bacterial and fungal flora.

[0093] 6. Quality Control

[0094] The complete nucleotide bases in the sample are determined by a sequencer, which generates short sequences or reads for each fragment in the library. Modern sequencing technologies generate a large number of sequence reads in just one experiment, but all of them have technical limitations. Next-generation sequencing can be affected by factors during library preparation and sequencing. This can negatively affect the quality of the raw data. Each sequencing program generates a different number of errors, such as reading incorrect nucleotides and deviations from the optimal library fragment size. For example, metagenomics processes a large library from the gut microbiome; therefore, one error will greatly affect the analysis of protein function and metabolic pathways of a specific gene. For meaningful downstream applications, quality control of the sequences seeks to identify and eliminate errors. This step helps researchers save time, energy, and resources.

[0095] The procedures of the quality control program should be performed at different time points of data processing, including the correct interpretation of the results, to ensure that the research conducted is meaningful. The assessment of raw sequencing data quality and depth, read duplication rate, and alignment quality is to improve the accuracy of the results. Rapid identification of poor quality samples relies on controlling the quality of the raw data. This means extra effort from the beginning to save time in later analysis. Alignment quality is critical for identifying low-quality samples that pass raw data quality control checks and for successful variant detection. In most exome sequencing studies, quality control of single nucleotide polymorphism (SNP) reads can identify poor samples and reduce the number of false positive SNP calls.

[0096] For example, quality control of NGS data can be difficult for different laboratories, which have varying resources (e.g., lack of expertise to perform the procedures). Therefore, standardization and simplification of NGS workflows involving quality control is a core requirement. Each checkpoint corresponds to a careful examination of the environment, protocols, results, and reagents.

[0097] There are two different pieces of equipment that are specifically used for QC in sequencing projects. The first is capillary gel electrophoresis, which studies the investigation of fragment size distribution and the final library quality assessment. The second most commonly used is a fluorometer, which is used for fluorescence quantification. In order to accurately quantify DNA / RNA in specific workflow steps and determine the final library quantity, systems such as quantitative PCR (qPCR) or digital droplet PCR (ddPCR) are recommended.

[0098] Sequence assembly and gene expression studies common in metagenomics require high-quality data. NGS technologies enable in-depth analysis of samples; however, they can still introduce sources of error and bias. Downplaying these sources or performing poor quality control can lead to serious problems such as confounding analytical results and sample contamination; this can undermine any claims and add to the certainty of biological results.

[0099] 7. Results

[0100] The BALF samples from rounds 1 to 10 were analyzed at different BALF sampling periods and then divided into 10 groups. According to the sequencing depth specified in this embodiment, there were 81 bacterial samples and 100 fungal samples.

[0101] 7.1α Diversity and community composition analysis

[0102] In the bacterial flora, patients with physical decline showed no significant difference in alpha diversity compared with those without physical decline ( Figures 1A-1E These two groups have 31 phyla and 685 genera ( Figure 1F and 1G ). Two sets of unique doors with the same level (4 vs. 3, Figure 1F ) and unique genera (309 vs. 213, Figure 1G ). Circos analysis showed that in the door ( Figure 1H ) and genus ( Fig. 1I ) level, there was no significant difference in the bacterial community composition between patients with physical decline and those without physical decline.

[0103] In the fungal community, patients with physical decline showed no significant differences in alpha diversity compared with those without physical decline ( Figure 2A-2E These two groups have 12 phyla and 344 genera in total ( Figure 2F and 2G ). Two sets of unique doors with the same level (0 vs. 1, Figure 2F ) and unique genera (124 vs. 156, Figure 2G ). Circos analysis showed that in the door ( Figure 2H ) and genus ( Fig.2I ) level, there was no significant difference in the fungal community composition between patients with physical decline and those without physical decline.

[0104] 7.2β-diversity analysis

[0105] PCA (P = 0.07, Figure 1J ) and PCoA (P = 0.001, Figure 1K ). The results showed that the bacterial communities of silicosis patients with and without physical decline were partially separated. PCA (P = 0.02, Figure 2J ) and PCoA (P = 0.001, Figure 2K ) Similar results were obtained in the β-diversity analysis of fungal communities.

[0106] 7.3LEfSe analysis

[0107] Compared with silicosis patients without physical decline, the physical decline group had higher levels of Vibrio, Faecalibacterium, and Dialister ( Figure 1N ) were significantly enriched, and Fusobacterium ( Figure 1M ) and Rhodococcus ( Figure 1N ) was significantly reduced. In the fungal community, P-mucoromycota ( Figure 2M ), G-ustilaginoidea, G-archeorhizomyces and G-unclassified-F-ceratobasidiaceae( Figure 2N ) have significant differences.

[0108] 7.4 Function Prediction

[0109] No significant differences were observed between silicosis patients with and without physical decline in the Kyoto Encyclopedia of Genes and Genomes (KEGG) classification. However, in enzymatic analysis, we found that the levels of β-glucosidase (46,842.51±16,170.78 vs. 33,881.42±14,172.59), glutamate synthetase (nicotinamide adenine dinucleotide phosphate, 42830.8±8,178.7 vs. 36,980.5±12,895.0) and glutamate synthetase (nicotinamide adenine dinucleotide phosphate, 42830.8±8,178.7 vs. 36,980.5±12,895.0) were higher in the physical decline group than in the group without physical decline ( Figure 3 ). In the fungal community, no significant differences in enzyme analysis were observed between silicosis patients with and without physical decline.

[0110] 7.5 Receiver Operating Characteristic (ROC) Analysis

[0111] To explore the role of BALF bacterial flora in predicting physical decline, random forest construction and ROC analysis were performed (in which 50% of the samples were randomly selected as training sets and the other 50% as test sets).

[0112] like Figure 4 The results showed that the abundance of Vibrio alone can distinguish silicosis patients with and without physical decline. When Vibrio vibrio was used as a biomarker, the area under the ROC curve [AUC] = 0.938, 95% confidence interval [CI] 0.870-1.000. This proves that Vibrio vibrio can effectively distinguish silicosis patients with and without physical decline.

[0113] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of a reagent for detecting the abundance of a biomarker in a sample in the preparation of a product for diagnosing physical decline in patients with silicosis, characterized in that: The biomarkers include Vibrio; The sample is bronchoalveolar lavage fluid.

2. The use according to claim 1, characterized in that: The product includes a test kit, a test paper, or a chip.